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Objectives: The GETAFIX trial will test the hypothesis that favipiravir is a more effective treatment for COVID-19
infection in patients who have early stage disease, compared to current standard of care. This study will also
provide an important opportunity to investigate the safety and tolerability of favipiravir, the pharmacokinetic and
pharmacodynamic profile of this drug and mechanisms of resistance in the context of COVID-19 infection, as well
as the effect of favipiravir on hospitalisation duration and the post COVID-19 health and psycho-social wellbeing of
patients recruited to the study.
Trial design: GETAFIX is an open label, parallel group, two arm phase II/III randomised trial with 1:1 treatment
allocation ratio. Patients will be randomised to one of two arms and the primary endpoint will assess the superiority
of favipiravir plus standard treatment compared to standard treatment alone.
Participants: This trial will recruit adult patients with confirmed positive valid COVID-19 test, who are not pregnant
or breastfeeding and have no prior major co-morbidities. This is a multi-centre trial, patients will be recruited from
in-patients and outpatients from three Glasgow hospitals: Royal Alexandra Hospital; Queen Elizabeth University
Hospital; and the Glasgow Royal Infirmary. Patients must meet all of the following criteria:
1. Age 16 or over at time of consent
2. Exhibiting symptoms associated with COVID-19
3. Positive for SARS-CoV-2 on valid COVID-19 test
4. Point 1, 2, 3, or 4 on the WHO COVID-19 ordinal severity scale at time of randomisation. (Asymptomatic with
positive valid COVID-19 test, Symptomatic Independent, Symptomatic assistance needed, Hospitalized, with no
oxygen therapy)
5. Have >=10% risk of death should they be admitted to hospital as defined by the ISARIC4C risk index: https://
isaric4c.net/risk
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6. Able to provide written informed consent
7. Negative pregnancy test (women of childbearing potential*)
8. Able to swallow oral medication
Patients will be excluded from the trial if they meet any of the following criteria:
1. Renal impairment requiring, or likely to require, dialysis or haemofiltration
2. Pregnant or breastfeeding
3. Of child bearing potential (women), or with female partners of child bearing potential (men) who do not agree
to use adequate contraceptive measures for the duration of the study and for 3 months after the completion of
study treatment
4. History of hereditary xanthinuria
5. Other patients judged unsuitable by the Principal Investigator or sub-Investigator
6. Known hypersensitivity to favipiravir, its metabolites or any excipients
7. Severe co-morbidities including: patients with severe hepatic impairment, defined as:
• greater than Child-Pugh grade A
• AST or ALT > 5 x ULN
• AST or ALT >3 x ULN and Total Bilirubin > 2xULN
8. More than 96 hours since first positive COVID-19 test sample was taken
9. Unable to discontinue contra-indicated concomitant medications
This is a multi-centre trial, patients will be recruited from in-patients and outpatients from three Glasgow hospitals:
Royal Alexandra Hospital; Queen Elizabeth University Hospital; and the Glasgow Royal Infirmary.
Intervention and comparator: Patients randomised to the experimental arm of GETAFIX will receive standard
treatment for COVID-19 at the discretion of the treating clinician plus favipiravir. These patients will receive a
loading dose of favipiravir on day 1 of 3600mg (1800mg 12 hours apart). On days 2-10, patients in the experimental
arm will receive a maintenance dose of favipiravir of 800mg 12 hours apart (total of 18 doses). Patients randomised
to the control arm of the GETAFIX trial will receive standard treatment for COVID-19 at the discretion of the treating
clinician.
Main outcomes: The primary outcome being assessed in the GETAFIX trial is the efficacy of favipiravir in addition
to standard treatment in patients with COVID-19 in reducing the severity of disease compared to standard
treatment alone. Disease severity will be assessed using WHO COVID 10 point ordinal severity scale at day 15 +/- 48
hours. All randomised participants will be followed up until death or 60 days post-randomisation (whichever is
sooner).
Randomisation: Patients will be randomised 1:1 to the experimental versus control arm using computer generated
random sequence allocation. A minimisation algorithm incorporating a random component will be used to allocate
patients. The factors used in the minimisation will be: site, age (16-50/51-70/71+), history of hypertension or
currently obsess (BMI>30 or obesity clinically evident; yes/no), 7 days duration of symptoms (yes/no/unknown), sex
(male/female), WHO COVID-19 ordinal severity score at baseline (1/2or 3/4).
Blinding (masking): No blinding will be used in the GETAFIX trial. Both participants and those assessing outcomes
will be aware of treatment allocation.
Numbers to be randomised (sample size): In total, 302 patients will be randomised to the GETAFIX trial: 151 to
the control arm and 151 to the experimental arm.
There will be an optional consent form for patients who may want to contribute to more frequent PK and PD
sampling. The maximum number of patients who will undergo this testing will be sixteen, eight males and eight
females. This option will be offered to all patients who are being treated in hospital at the time of taking informed
consent, however only patients in the experimental arm of the trial will be able to undergo this testing.
Trial Status: The current GETAFIX protocol is version 4.0 12th September 2020. GETAFIX opened to recruitment on
26th October 2020 and will recruit patients over a period of approximately six months.
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Trial registration: GETAFIX was registered on the European Union Drug Regulating Authorities Clinical Trials
(EudraCT) Database on 15th April 2020; Reference number 2020-001904-41 (https://www.clinicaltrialsregister.eu/ctr-
search/trial/2020-001904-41/GB). GETAFIX was registered on ISRCTN on 7th September 2020; Reference number ISRC
TN31062548 (https://www.isrctn.com/ISRCTN31062548).
Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter
serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance
with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (see
Additional file 2).
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Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04891-1.
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